Recent studies into retatruptide peptide demonstrate promising outlook for addressing weight and non-insulin dependent diabetes. The molecule, a dual activator of glucagon-like peptide-1 and GIP receptor, seems to offer improved weight reduction and glucose regulation versus existing therapies. A